Drugstore Blog News

An verbal allergy treatment administered in drops under the tongue is a guarded and effective alternative to injections for adults who are allergic to ragweed pollen, according to a study published in the Journal of Allergy and Clinical Immunology by means of allergic indisposition specialist at Allegheny General Hospital.

Widely used in Europe, but not yet approved through the U.S. Food and Drug Administration, sublingual allergen immunotherapy (SLIT) can subsist a more useful and tolerable management approach that leads to greater indulgent compliance, said David Skoner, MD, director of AGH’s Division of Allergy, Asthma and Immunology and a co-lead investigator in the study.

“The study’session findings distinguish by a mark a step forward in gaining approval for sublingual administration of allergy medication,” said Dr. Skoner, “We believe a large number of patients would greatly benefit from having access to this new parole treatment to ease their symptoms.”

“The sublingual method so far has been safe, and the adherence rate should be victory since no injections are involved and the medication is administered at home,” said co-investigator Deborah Gentile, MD, Director of Research in AGH’s Division of Allergy, Asthma and Immunology.

The AGH subject of attention, “Sublingual Immunotherapy in Patients with Allergic Rhinoconjunctivitis Caused by dint of. Ragweed Pollen,” involved 115 patients in Pittsburgh, Madison, Wisc., Iowa City and Evansville, Ind. They were randomly assigned to a medium or extreme draught of standardized glycerinated imperfect ragweed pollen draw out or to a placebo. Participants kept diaries to monitor their symptoms over the course of 17 weeks during the ragweed pollen acclimatize.

The frequency of quotidian symptoms, as well as the strait with a view to additional medication to treat symptoms, both dropped significantly on the side of those apprehension the high-dose medication, against those anger a placebo. The frequency of adverse events was similar between the placebo and treatment groups.

The researchers concluded that SLIT was safe and can master symptoms in ragweed-sensitive patients, notwithstanding that again trials are needed to definitively establish the method’s potency.

Shortcomings of former trials with the sublingual method included small patient populations, southerly withdrawals and lacking treatment time. Questions remaining on SLIT hold treatment schedules, optimal doses and cost-effectiveness.

Other researchers involved in the think were Robert Bush, MD of the University of Wisconsin School of Medicine and Public Health; Mary Beth Fasano, MD, University of Iowa Hospitals and Clinics; Anne McLaughlin, MD, of Wellborn Clinical Research Center in Evansville, Ind., and Robert E. Esch, PhD, of Greer Laboratories Inc., Lenoir, NC.

Source: Allegheny General Hospital

Comments are closed.